Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science HoldingsASX:EZZ +14.29%52 EV-to-EBIT is 2.84 as of Aug. 29, 2026, which is 6% below its 10-year median of 3.03. GuruFocus rates ASX:EZZ with a GF Score™ of 52/100 and a GF Value™ of A$1.47 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 380 Biotechnology companies, EZZ Life Science Holdings ranks better than 75.53% on this metric.
EZZ Life Science Holdings (ASX:EZZ) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
EZZ Life Science Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was A$53.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings EV-to-EBIT Related Terms
EZZ Life Science Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EZZ vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's EV-to-EBIT falls into.
EZZ Life Science Holdings's current Enterprise Value is A$16.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings (ASX:EZZ) has a EV-to-EBIT of 2.84 as of Aug. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EZZ Life Science Holdings and its competitors. This is near median its historical median of 3.03. According to the industry distribution chart, EZZ Life Science Holdings ranks #93 out of 380 companies in the Biotechnology industry, placing it in the top 24.5%.
Is EZZ Life Science Holdings' EV-to-EBIT too high?
EZZ Life Science Holdings' current EV-to-EBIT of 2.84 is near median its 10-year median of 3.03. The Biotechnology industry median EV-to-EBIT is 15.99. EZZ Life Science Holdings' value of 2.84 is 82.2% below this industry median. Based on the distribution chart, EZZ Life Science Holdings ranks #93 out of 380 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, EZZ Life Science Holdings has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #93 out of 380 companies for EV-to-EBIT. This places EZZ Life Science Holdings in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.99. EZZ Life Science Holdings' value of 2.84 is 82.2% below this benchmark. While the company's 10-year median is 3.03 vs. the industry median of 15.99, EZZ Life Science Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.99, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EZZ Life Science Holdings's current EV-to-EBIT of 2.84 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EZZ Life Science Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EZZ Life Science Holdings's current EV-to-EBIT is 2.84, which is near median its own 10-year median of 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.47, compared to a current price of A$0.64 — trading 56.5% below its estimated fair value. The current EV-to-EBIT is 2.84, which is near median its 10-year median of 3.03 and 82.2% below the Biotechnology industry median of 15.99. EZZ Life Science Holdings' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current EV-to-EBIT is 2.84 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.64 is trading 56.5% below its estimated GF Value™ of A$1.47.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
EV-to-EBIT: 2.84 (near median its 10-year median of 3.03)
GF Value™: A$1.47 vs. price of A$0.64 (56.5% below fair value)
Industry Position: 82.2% below the Biotechnology median (#93 of 380)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
52GF Score
Get the complete analysis for ASX:EZZ
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
